Patrick John Finn Sells 2,058 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,058 shares of the business’s stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now directly owns 265,460 shares in the company, valued at $10,615,745.40. This represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total transaction of $7,978.38.
• On Monday, February 3rd, Patrick John Finn sold 2,845 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $140,400.75.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $40.11 on Monday. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -11.87 and a beta of 2.34. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average is $39.67 and its two-hundred day moving average is $44.29. Twist Bioscience Co. has a 12-month low of $30.32 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.75) EPS. Research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after acquiring an additional 189,791 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after buying an additional 532,040 shares in the last quarter. Geode Capital Management LLC lifted its position in Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock worth $63,895,000 after acquiring an additional 6,908 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new position in Twist Bioscience in the 4th quarter worth approximately $56,984,000.

Analyst Ratings Changes

TWST has been the topic of a number of recent analyst reports. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Barclays lowered their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.